25.22 % to Target, Leerink Swann Maintains Outperform Rating for Alexion Pharmaceuticals Inc (NDAQ:ALXN) Stock

Share with your friends


London Alexion Pharmaceuticals Inc. NDAQ:ALXN

Alexion Pharmaceuticals Inc (NDAQ:ALXN) Rating Kept

EU: In a research note released on Wednesday, 13 September, Leerink Swann reiterated their Outperform rating on shares of Alexion Pharmaceuticals Inc (NDAQ:ALXN). They currently have a $182.00 target price on the company. Leerink Swann’s target would indicate a potential upside of 25.22 % from the company’s last stock close price.

NDAQ:ALXN is right now trading 1.66% higher at $146.46 as of 8:01 AM New York time. Alexion Pharmaceuticals Inc.’s stock is 0% in the last 200 days. It has underperformed the S&P 500 Index, which has gained 6.00% in the same time.

According to data compiled by Thomson Reuters, Alexion Pharmaceuticals Inc (NDAQ:ALXN)’s stock is covered by 18 equity analysts across the Street, with 0 analysts giving it a Sell rating, 13 a Buy rating, while 7 consider it a Hold. The 12-month consensus target price for the stock is $187.61, which reflects an upside potential of 28.10% over the current price.

ALXN Stock Chart

Institutional Ownership

Baker Bros. Advisors Lp had the most significant stake with ownership of 6.54M shares as of Q2 2015 for 7.28% of the stock exposure. Lagoda Investment Management L.P. is another quite bullish investment professional who is owning 157,853 shares of Alexion Pharmaceuticals Inc. or 5.82% of their stock exposure. Furthermore, Bb Biotech Ag have 5.08% of their stock exposure invested in the company for 1.18M shares. The New York-based fund Healthcor Management L.P. revealed it had purchased so far a stake worth about 4.85% of the investment professional’s stock portfolio in Alexion Pharmaceuticals Inc.. The Connecticut-based fund March Altus Capital Management Lp is also positive about the stock, possessing 650,000 shares or 4.75% of their stock exposure.

Alexion Pharmaceuticals Inc (NDAQ:ALXN) Profile

Alexion Pharmaceuticals IncAlexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Alexion Pharmaceuticals Inc (NDAQ:ALXN) traded up 1.66% on 13 September, hitting $146.46. A total of 1.66M shares of the company’s stock traded hands. This is up from average of 1.48M shares. Alexion Pharmaceuticals Inc. has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a market cap of $32.69B and a P/E ratio of 63.47.

Get the latest Alexion Pharmaceuticals Inc (NDAQ:ALXN) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.